Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.
Minae AnArnav MehtaByung-Hoon MinYou Jeong HeoSamuel J WrightMilan ParikhLynn BiHyuk LeeTae Jun KimSong-Yi LeeJeonghyeon MoonRyan J ParkMatthew R StricklandWoong-Yang ParkWon Ki KangKyoung-Mee KimSeung Tae KimSamuel J KlempnerJeeyun LeePublished in: Cancer discovery (2024)
The benefit of 5-FU/platinum with anti-PD-1 in first-line advanced gastric cancer is limited to patient subgroups. Using a trial with sequential anti-PD-1, we show coordinated induction of multicellular TME hubs informs the ability of anti-PD-1 to potentiate T cell-driven responses. Differential TME hub development highlights features that underlie clinical outcomes. This article is featured in Selected Articles from This Issue, p. 695.